Skip to content
  1. Home
  2. >Clinical Genomics
  3. >Carrier Screening
  4. >Expanded Carrier Screen
Back to catalog

Expanded Carrier Screen

An expanded carrier screen evaluating 115 genes (females) or 99 genes (males) for autosomal recessive and X-linked disorders with carrier frequency ≥1/200, powered by the Helix Exome+® platform.

Turnaround

7-14 days

Test Description

The Helix Expanded Carrier Screen analyzes 115 genes associated with serious inherited conditions, aligned with ACMG Tier 3 guidelines. This comprehensive panel covers conditions with a carrier frequency greater than 1 in 200.

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

Indications for Testing

Prenatal or preconception risk assessment for individuals who are pregnant or planning to conceive.

Methodology

This test utilizes next-generation sequencing to detect single nucleotide variants, insertions and deletions up to 20 bp, and copy number variants in genes associated with autosomal recessive and X-linked inherited disorders.

Technical Specifications

Gene notesBTD: If detected, the variant NM_001370658.1:c.1270G>C (p.Asp424His) will not be reported. CFTR: Analysis of the intron 8 polymorphic region is only performed if p.Arg117His is detected. Single exon d... Genomic buildGRCh37

Genes Tested

ABCA3
ABCC8
ABCD1
ACADM
ACADVL
ACAT1
AGA
AGXT
AHI1
AIRE
ALDOB
ALPL
ANO10
ARSA
ARX
ASL
ASPA
ATP7B
BBS1
BBS2
BCKDHB
BLM
BTD
CBS
CC2DA2

Showing 25 of 115 genes in this panel

Other Tests to Consider

Important Panel Information

Turnaround time: Typically 7 to 21 days

Preferred specimen: Oragene Dx Saliva Collection Kit

Shipping instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

The genes on this panel are well understood in the literature, have clearly defined strong gene-disease associations with inherited conditions that present as profound, severe, or moderate as classified by ACMG, and have widely available prenatal diagnosis.

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.